Call us today 212-583-0100

ENZO Biochem Announces Appointment Of James M. O’Brien As Senior VP, Finance

NEW YORK, NY, May 30, 2014 – Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biosciences and clinical laboratory company, announced today the appointment of James M. O’Brien as Senior Vice President, Finance.
“Jim has an impressive professional background and brings over 15 years of experience leading and managing all financial functions for a number of diverse global organizations.  Jim has held leadership positions in the areas of planning and strategic development, financial analysis, SEC reporting and internal controls for both large and small multi-national public companies,” said Barry Weiner, President of Enzo Biochem, Inc.  “We are excited that Jim has joined our team and we look forward to his input and assistance in strengthening and adding value to our Company.”
Most recently Mr. O’Brien was Vice President and Corporate Controller for Actavis, plc., (NYSE:ACT) a multi-billion global specialty pharmaceutical company. Previously, he held senior level finance positions with Nycomed US, Aptuit, Inc., Purdue Pharma LLP and Bristol Myers Squibb Company.  Mr. O’Brien began his career in public accounting with PricewaterhouseCoopers LLP. He holds a BA from George Washington University and an MBA in Finance from Fordham University.  Jim achieved his CPA in 1992.
Separately, Mr. Weiner also commented on the recent departures of Andrew Crescenzo, who Mr. O’Brien succeeds, and Andrew Whiteley, formerly COO of Enzo Life Sciences.  “We appreciate the contributions and years of service that both Drew and Andrew provided to the Company, and we wish them well.”
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2013. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
For Enzo Biochem, Inc.
Steven Anreder                                                           Michael Wachs
Anreder & Company                                                   CEOcast, Inc.
212-532-3232                                                              212-732-4300 or